461 related articles for article (PubMed ID: 31444180)
1. PCASTt/SPCG-17-a randomised trial of active surveillance in prostate cancer: rationale and design.
Ahlberg MS; Adami HO; Beckmann K; Bertilsson H; Bratt O; Cahill D; Egevad L; Garmo H; Holmberg L; Johansson E; Rannikko A; Van Hemelrijck M; Jäderling F; Wassberg C; Åberg UWN; Bill-Axelson A
BMJ Open; 2019 Aug; 9(8):e027860. PubMed ID: 31444180
[TBL] [Abstract][Full Text] [Related]
2. Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.
Hamdy FC; Donovan JL; Lane JA; Mason M; Metcalfe C; Holding P; Wade J; Noble S; Garfield K; Young G; Davis M; Peters TJ; Turner EL; Martin RM; Oxley J; Robinson M; Staffurth J; Walsh E; Blazeby J; Bryant R; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Gnanapragasam V; Hughes O; Kockelbergh R; Kynaston H; Paul A; Paez E; Powell P; Prescott S; Rosario D; Rowe E; Neal D
Health Technol Assess; 2020 Aug; 24(37):1-176. PubMed ID: 32773013
[TBL] [Abstract][Full Text] [Related]
3. Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial.
Lane JA; Donovan JL; Davis M; Walsh E; Dedman D; Down L; Turner EL; Mason MD; Metcalfe C; Peters TJ; Martin RM; Neal DE; Hamdy FC;
Lancet Oncol; 2014 Sep; 15(10):1109-18. PubMed ID: 25163905
[TBL] [Abstract][Full Text] [Related]
4. Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy.
Willemse PM; Davis NF; Grivas N; Zattoni F; Lardas M; Briers E; Cumberbatch MG; De Santis M; Dell'Oglio P; Donaldson JF; Fossati N; Gandaglia G; Gillessen S; Grummet JP; Henry AM; Liew M; MacLennan S; Mason MD; Moris L; Plass K; O'Hanlon S; Omar MI; Oprea-Lager DE; Pang KH; Paterson CC; Ploussard G; Rouvière O; Schoots IG; Tilki D; van den Bergh RCN; Van den Broeck T; van der Kwast TH; van der Poel HG; Wiegel T; Yuan CY; Cornford P; Mottet N; Lam TBL
Eur Urol; 2022 Apr; 81(4):337-346. PubMed ID: 34980492
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
6. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
7. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial.
Johansson E; Steineck G; Holmberg L; Johansson JE; Nyberg T; Ruutu M; Bill-Axelson A;
Lancet Oncol; 2011 Sep; 12(9):891-9. PubMed ID: 21821474
[TBL] [Abstract][Full Text] [Related]
8. Magnetic Resonance Imaging-Guided Confirmatory Biopsy for Initiating Active Surveillance of Prostate Cancer.
Jayadevan R; Felker ER; Kwan L; Barsa DE; Zhang H; Sisk AE; Delfin M; Marks LS
JAMA Netw Open; 2019 Sep; 2(9):e1911019. PubMed ID: 31509206
[TBL] [Abstract][Full Text] [Related]
9. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626
[TBL] [Abstract][Full Text] [Related]
10. Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial.
Klotz L; Loblaw A; Sugar L; Moussa M; Berman DM; Van der Kwast T; Vesprini D; Milot L; Kebabdjian M; Fleshner N; Ghai S; Chin J; Pond GR; Haider M
Eur Urol; 2019 Feb; 75(2):300-309. PubMed ID: 30017404
[TBL] [Abstract][Full Text] [Related]
11. Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers.
Bokhorst LP; Alberts AR; Rannikko A; Valdagni R; Pickles T; Kakehi Y; Bangma CH; Roobol MJ;
Eur Urol; 2015 Nov; 68(5):814-21. PubMed ID: 26138043
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Outcomes after Deferred Radical Prostatectomy in Men Initially Treated with Active Surveillance.
Godtman RA; Schafferer M; Pihl CG; Stranne J; Hugosson J
J Urol; 2018 Oct; 200(4):779-785. PubMed ID: 29730198
[TBL] [Abstract][Full Text] [Related]
13. A Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-based Prostate Biopsy in Men on Active Surveillance for Prostate Cancer-Data from the International Multicenter Prospective PRIAS Study.
Luiting HB; Remmers S; Boevé ER; Valdagni R; Chiu PK; Semjonow A; Berge V; Tully KH; Rannikko AS; Staerman F; Roobol MJ
Eur Urol Oncol; 2022 Dec; 5(6):651-658. PubMed ID: 35437217
[TBL] [Abstract][Full Text] [Related]
14. Nine-year Follow-up for a Study of Diffusion-weighted Magnetic Resonance Imaging in a Prospective Prostate Cancer Active Surveillance Cohort.
Henderson DR; de Souza NM; Thomas K; Riches SF; Morgan VA; Sohaib SA; Dearnaley DP; Parker CC; van As NJ
Eur Urol; 2016 Jun; 69(6):1028-33. PubMed ID: 26482887
[TBL] [Abstract][Full Text] [Related]
15. An evidence review of active surveillance in men with localized prostate cancer.
Ip S; Dahabreh IJ; Chung M; Yu WW; Balk EM; Iovin RC; Mathew P; Luongo T; Dvorak T; Lau J
Evid Rep Technol Assess (Full Rep); 2011 Dec; (204):1-341. PubMed ID: 23126653
[TBL] [Abstract][Full Text] [Related]
16. A single-center long-term experience of active surveillance for prostate cancer: 15 years of follow-up.
Song SH; Kim JK; Lee H; Lee S; Hong SK; Byun SS
Investig Clin Urol; 2021 Jan; 62(1):32-38. PubMed ID: 33258324
[TBL] [Abstract][Full Text] [Related]
17. Active surveillance strategy for patients with localised prostate cancer: criteria for progression.
Thomsen FB
Dan Med J; 2015 Feb; 62(2):. PubMed ID: 25634510
[TBL] [Abstract][Full Text] [Related]
18. The Value of an Extensive Transrectal Repeat Biopsy with Anterior Sampling in Men on Active Surveillance for Low-risk Prostate Cancer: A Comparison from the Randomised Study of Active Monitoring in Sweden (SAMS).
Bratt O; Holmberg E; Andrén O; Carlsson S; Drevin L; Johansson E; Josefsson A; Nyberg M; Sandberg J; Stattin P; Robinsson D
Eur Urol; 2019 Oct; 76(4):461-466. PubMed ID: 30878303
[TBL] [Abstract][Full Text] [Related]
19. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
[TBL] [Abstract][Full Text] [Related]
20. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]